ITTs as described above could only be used safely (i.e. without life-threatening hypoglycaemia) to provide a limited decrease in blood glucose levels (to ~ 4 mM), above the usual threshold for substantial glucagon release in the mouse [29]. Here, GCG is linked to Hypoglycemia.